+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glaucoma Treatment Market by Treatment Type, Drug Class, Route of Administration, Product Type, Distribution Channel, End Use - Global Forecast to 2030- Product Image
Glaucoma Treatment Market by Treatment Type, Drug Class, Route of Administration, Product Type, Distribution Channel, End Use - Global Forecast to 2030- Product Image
Sale

Glaucoma Treatment Market by Treatment Type, Drug Class, Route of Administration, Product Type, Distribution Channel, End Use - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305564
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Glaucoma Treatment Market grew from USD 7.31 billion in 2024 to USD 7.99 billion in 2025. It is expected to continue growing at a CAGR of 9.03%, reaching USD 12.28 billion by 2030.

Understanding the Transforming Glaucoma Treatment Dynamics

Glaucoma remains one of the leading causes of irreversible blindness worldwide, prompting an urgent need for innovation across diagnostic, therapeutic, and management approaches. This executive summary unpacks the evolving landscape of glaucoma treatment, highlighting the confluence of technological breakthroughs, shifting regulatory environments, and patient-centric care models that are redefining standards of practice.

As healthcare systems intensify their focus on value-based outcomes, clinicians and industry stakeholders are collaborating to optimize treatment pathways. From minimally invasive surgical techniques to novel pharmacological modalities, the emphasis has shifted toward improving long-term ocular health while reducing patient-burden and total cost of care. This transformation is driven by advances in imaging, drug delivery systems, and a robust pipeline of next-generation therapeutics.

Throughout this summary, you will discover the key transformative shifts reshaping glaucoma care, an analysis of significant policy interventions such as the United States tariffs set for 2025, and critical insights derived from market segmentation. Regional dynamics and competitive landscape evaluations provide further context, while strategic recommendations offer a roadmap for decision-makers. Finally, a detailed methodology section elucidates our research approach to ensure transparency and rigor.

Emerging Disruptions Reshaping Glaucoma Care

The glaucoma treatment paradigm is experiencing unprecedented disruption, driven by a convergence of emerging technologies and evolving regulatory frameworks. Precision laser therapies have progressed beyond traditional argon systems to selective and endocyclophotocoagulation techniques, enabling targeted reduction of intraocular pressure with minimal collateral damage. Concurrently, sustained-release drug implants are gaining traction, offering consistent therapeutic levels and enhanced patient adherence compared to topical eye drops.

Regulators are actively engaging with industry to streamline approval pathways for breakthrough devices and novel pharmacological agents, responding to advocacy for faster patient access. Digital health platforms, powered by artificial intelligence, are now supporting remote monitoring of disease progression, facilitating timely clinical interventions while reducing the frequency of in-office visits.

Strategic partnerships between device manufacturers and pharmaceutical companies have emerged as a hallmark of this transformation, blending complementary expertise to deliver integrated care solutions. Moreover, patient advocacy groups are influencing trial design to foreground quality-of-life metrics, further aligning research priorities with real-world needs. These cumulative shifts are not only enhancing therapeutic efficacy but also broadening the horizon for personalized glaucoma management.

Evaluating the 2025 US Tariff Implications on Treatment Accessibility

The introduction of new tariffs on ophthalmic instruments and pharmaceutical imports in the United States is poised to exert multidimensional pressures on cost structures and supply chains. Devices integral to laser trabeculoplasty and minimally invasive procedures may see import levies applied to key components, leading manufacturers to re-evaluate sourcing strategies or adjust pricing models. In parallel, tariffs on active pharmaceutical ingredients used in prostaglandin analogs and newer rho kinase inhibitors could affect the economics of generic and branded drug portfolios alike.

As distributors and providers navigate these changes, there is an increased emphasis on local manufacturing partnerships and vertical integration to mitigate tariff impacts. Some firms are already exploring production realignment toward domestic facilities or tariff-exempt trade agreements to sustain margins without compromising access. Ultimately, the cost pressure may be shared across the value chain, with payers and patients potentially facing higher out-of-pocket expenses unless strategic cost absorption measures are implemented.

Moving forward, rigorous scenario planning and proactive engagement with policymakers will be essential for stakeholders to anticipate further adjustments to trade policies. By building resilient supply chains and evaluating alternative sourcing options, industry participants can preserve treatment affordability and continuity of care despite escalating trade tensions.

Deep Dive into Critical Market Segmentation Patterns

A granular understanding of market segmentation reveals where innovation and unmet need intersect. When dissecting treatment type, laser approaches span from traditional argon laser trabeculoplasty to emerging selective laser modalities and endocyclophotocoagulation, each offering unique safety and efficacy profiles. Medical therapy encompasses a spectrum of drug classes, including alpha agonists and beta blockers that have long formed the backbone of intraocular pressure control, alongside newer carbonic anhydrase inhibitors, miotics, prostaglandin analogs, and the latest rho kinase inhibitors that deliver targeted mechanism-driven benefits.

Further differentiation arises in route of administration, where sustained-release implants redefine adherence paradigms compared to systemic or topical regimens. Product type segmentation distinguishes between branded innovations with premium pricing and generics that drive volume and accessibility. Distribution channels vary widely from hospital pharmacies and ophthalmology clinic dispensaries to online and retail pharmacies, each with distinct procurement processes and regulatory considerations. End use segmentation captures the diversity of care settings, from specialized ambulatory surgery centers and high-volume hospital systems to homecare services and dedicated eye clinics, reflecting how patients engage with the healthcare continuum.

Integrating these layers of segmentation enables stakeholders to pinpoint high-value opportunities and tailor strategies across the therapeutic lifecycle. Such a nuanced lens brings clarity to where clinical demand intersects with economic viability, informing everything from clinical trial prioritization to go-to-market deployment plans.

Regional Perspectives Driving Market Variance

Regional dynamics play a pivotal role in shaping glaucoma treatment adoption and innovation. In the Americas, robust reimbursement frameworks and high healthcare expenditure underpin rapid uptake of minimally invasive surgical techniques and advanced drug delivery systems, though challenges persist in extending equitable access across underserved communities. Conversely, Europe, Middle East & Africa presents a mosaic of healthcare models, with Western European markets leading in early adoption of novel devices, while emerging markets in the Middle East and Africa concentrate on expanding basic diagnostic and treatment infrastructure to address significant unmet need.

In Asia-Pacific, the confluence of rapidly aging populations and aggressive government initiatives to bolster local manufacturing fosters a dynamic environment. Countries such as Japan and Australia act as innovation hubs for both photonics-driven interventions and next-generation pharmaceuticals, while markets like China and India leverage economies of scale to produce cost-competitive generic therapies. Each region’s regulatory cadence, payer structure, and population health profile inform nuanced market access strategies, demanding that industry players calibrate their commercial models to local imperatives.

Strategic Moves by Leading Market Players

Leading manufacturers and pharmaceutical firms are intensifying their focus on integrating complementary platforms to deliver holistic glaucoma care solutions. Device specialists are forging collaborations with biotech innovators to co-develop next-generation sustained-release implants, while pharmaceutical companies are investing in laser technologies to complement their existing drug franchises. Several organizations have executed strategic acquisitions to consolidate intellectual property portfolios, spanning from gene therapy concepts to advanced imaging algorithms that enable earlier disease detection.

Meanwhile, incumbents are fortifying their global footprints by securing manufacturing capacities across key geographies, ensuring supply continuity and regulatory compliance. Joint ventures have emerged as a popular vehicle for market entry into regions with variable reimbursement and distribution landscapes, facilitating risk sharing and local expertise exchange. Innovation roadmaps prioritize minimally invasive approaches and novel molecular targets, underscoring a shift from symptom management toward neuroprotective and regenerative strategies within the glaucomatous optic nerve.

Strategic Imperatives for Stakeholders in Glaucoma Care

Industry stakeholders must adopt a multi-pronged approach to harness the full potential of emerging trends. Investment in research and development should focus on bridging the gap between device and drug modalities, fostering integrated solutions that improve patient outcomes and streamline clinical workflows. Regulatory engagement must be proactive, leveraging real-world evidence to validate safety and efficacy while advocating for accelerated pathways for breakthrough interventions.

Commercial strategies should emphasize value demonstration, using health economics and outcomes research to articulate the total cost of care benefits associated with sustained-release drug products and minimally invasive procedures. Expanding partnerships with distribution channels, particularly in online pharmacy models, can enhance geographic reach and patient convenience. Finally, digital health platforms must be incorporated into patient engagement frameworks, enabling remote monitoring and personalized adherence support to sustain long-term vision preservation.

Rigorous Multi-Source Research Framework

This analysis is underpinned by a comprehensive research framework that triangulates primary and secondary sources to ensure robust and unbiased insights. Primary research included detailed interviews with key opinion leaders, spanning ophthalmologists, clinical trial investigators, payer representatives, and senior executives within device and pharmaceutical companies. These discussions were complemented by a systematic review of peer-reviewed journals, regulatory filings, and clinical trial registries to validate emerging therapeutic mechanisms and device innovations.

Secondary research entailed the analysis of industry reports, financial statements, patent databases, and government publications to map competitive dynamics and policy shifts. Data points were cross-verified through multiple channels to minimize discrepancies, and qualitative findings were synthesized using rigorous thematic analysis. Quality control measures included peer reviews by subject matter experts to uphold methodological integrity and ensure that the conclusions drawn accurately reflect current industry realities.

Synthesis of Insights and Future Outlook

The glaucoma treatment landscape is undergoing a profound transformation, driven by technological innovation, evolving drug modalities, and dynamic policy interventions. Layered segmentation insights reveal strategic inflection points from surgical techniques to distribution channels, while regional analyses highlight the importance of localized market approaches. Competitive intelligence underscores the value of strategic alliances and portfolio diversification in sustaining growth and addressing unmet clinical needs.

Looking ahead, resilience in the face of trade policy changes and regulatory evolution will be equally critical. Organizations equipped with integrated, data-driven strategies will be best positioned to navigate uncertainty and capture emerging opportunities. By synthesizing these insights, decision-makers can chart a course toward improved patient outcomes, enhanced operational efficiency, and sustained market leadership in the field of glaucoma care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Laser Treatment
      • Argon Laser Trabeculoplasty
      • Endocyclophotocoagulation
      • Selective Laser Trabeculoplasty
    • Medical Treatment
    • Surgical Treatment
      • Drainage Device Implantation
      • Minimally Invasive Glaucoma Surgery
        • Hydrus
        • IStent
        • Xen Gel Stent
      • Trabeculectomy
  • Drug Class
    • Alpha Agonists
    • Beta Blockers
    • Carbonic Anhydrase Inhibitors
    • Miotics
    • Prostaglandin Analogs
    • Rho Kinase Inhibitors
  • Route Of Administration
    • Sustained Release
    • Systemic
    • Topical
  • Product Type
    • Branded
    • Generic
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End Use
    • Ambulatory Surgery Centers
    • Homecare
    • Hospitals
    • Ophthalmology Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Bausch & Lomb Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Théa Pharma International SAS
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Glaucoma Treatment Market, by Treatment Type
8.1. Introduction
8.2. Laser Treatment
8.2.1. Argon Laser Trabeculoplasty
8.2.2. Endocyclophotocoagulation
8.2.3. Selective Laser Trabeculoplasty
8.3. Medical Treatment
8.4. Surgical Treatment
8.4.1. Drainage Device Implantation
8.4.2. Minimally Invasive Glaucoma Surgery
8.4.2.1. Hydrus
8.4.2.2. IStent
8.4.2.3. Xen Gel Stent
8.4.3. Trabeculectomy
9. Glaucoma Treatment Market, by Drug Class
9.1. Introduction
9.2. Alpha Agonists
9.3. Beta Blockers
9.4. Carbonic Anhydrase Inhibitors
9.5. Miotics
9.6. Prostaglandin Analogs
9.7. Rho Kinase Inhibitors
10. Glaucoma Treatment Market, by Route of Administration
10.1. Introduction
10.2. Sustained Release
10.3. Systemic
10.4. Topical
11. Glaucoma Treatment Market, by Product Type
11.1. Introduction
11.2. Branded
11.3. Generic
12. Glaucoma Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Glaucoma Treatment Market, by End Use
13.1. Introduction
13.2. Ambulatory Surgery Centers
13.3. Homecare
13.4. Hospitals
13.5. Ophthalmology Clinics
14. Americas Glaucoma Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Glaucoma Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Glaucoma Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Novartis AG
17.3.3. Pfizer Inc.
17.3.4. Santen Pharmaceutical Co., Ltd.
17.3.5. Merck & Co., Inc.
17.3.6. Bausch & Lomb Corporation
17.3.7. Sun Pharmaceutical Industries Ltd.
17.3.8. Aerie Pharmaceuticals, Inc.
17.3.9. Théa Pharma International SAS
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GLAUCOMA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. GLAUCOMA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. GLAUCOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GLAUCOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ARGON LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ENDOCYCLOPHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SELECTIVE LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRAINAGE DEVICE IMPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HYDRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ISTENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY XEN GEL STENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TRABECULECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 69. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 147. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 150. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 151. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 160. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 195. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 196. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 210. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 214. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 221. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 223. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 248. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 249. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 250. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 257. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 259. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 275. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 276. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 277. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 282. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 284. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 285. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 286. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 310. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 312. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 313. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 314. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 315. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 317. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 319. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 320. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 321. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 322. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 323. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 326. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 328. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 329. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 330. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 331. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2030 (USD MILLION)
TABLE 332. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. JAPAN GLAUCOMA TREATMEN

Companies Mentioned

The companies profiled in this Glaucoma Treatment market report include:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Bausch & Lomb Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Théa Pharma International SAS
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.99 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.28 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Minimally Invasive Glaucoma Surgery Devices Market by Mechanism, End User, Distribution Channel, Indication - Global Forecast to 2030 - Product Image

Minimally Invasive Glaucoma Surgery Devices Market by Mechanism, End User, Distribution Channel, Indication - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Glaucoma Market by Product Type, End User, Distribution Channel, Route of Administration - Global Forecast to 2030 - Product Image

Glaucoma Market by Product Type, End User, Distribution Channel, Route of Administration - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2024-2032 - Product Image

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Open-Angle Glaucoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Open-Angle Glaucoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Micro Invasive Glaucoma Surgery (MIGS) Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Micro Invasive Glaucoma Surgery (MIGS) Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From

About the Glaucoma Drug Market

The Glaucoma Drug market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. Glaucoma is a group of eye diseases that cause damage to the optic nerve, resulting in vision loss. Glaucoma drugs are used to reduce intraocular pressure, which is the main risk factor for glaucoma. These drugs can be administered orally, topically, or through injections. Commonly used glaucoma drugs include prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and cholinergic agonists. Some of the major companies in the Glaucoma Drug market include Allergan, Pfizer, Merck, Novartis, Bausch Health, Sun Pharmaceuticals, Santen Pharmaceuticals, and Alcon. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.